Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus CANTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus CANTIL.
BENTYL vs CANTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
None Documented
None Documented
1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Category C
Category C
Anticholinergic
Anticholinergic / Antispasmodic